Femasys stock.

Historical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. ... Femasys Inc. Quote. Stocks to Consider.FEMY Earnings Date and Information. Femasys has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More.Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Stock Info Stock Quote Price $1.03 Volume 3,368,658 Change +0.12 % Change +12.72% Today's Open $0.96 Previous Close $0.91 Intraday High $1.14 Intraday …Web

12 Health Care Stocks Moving In Wednesday's After-Market Session. Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWebAIM ImmunoTech Inc. 0.47. -0.002. -0.4237%. Get Femasys Inc (FEMY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Oct 3, 2023 · Femasys Inc. FEMY shares are trading lower Tuesday. The stock has been volatile since the company received FDA 510(k) clearance for FemaSeed, an infertility treatment, towards the end of September . Femasys has a market capitalisation of US$22m and burnt through US$11m last year, which is 50% of the company's market value. ... It does not constitute a recommendation to buy or sell any stock ...

Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock …WebNov 30, 2023 · According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy. Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. ... Femasys Inc. Quote. Stocks to Consider.-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys --ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible …The latest price target for Femasys (NASDAQ: FEMY) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a price target for ...

Oct 11, 2023 · Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

Femasys story: Femasys Inc Shares Close the Day 14.4 percent Lower - Daily Wrap - Nasdaq and other headlines for Femasys Stock

With 11.8mil shares outstanding and a share price of $7.5, the market cap of Femasys is $88.5mil and with a cash position of $33mil, the enterprise value of the company is expected to be $55.5mil ...Nov 29, 2023 · 3 equities research analysts have issued twelve-month price targets for Femasys' shares. Their FEMY share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 884.9% from the stock's current price. View analysts price targets for FEMY or ... ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ...Find the latest Earnings Report Date for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.Oct 11, 2023 · Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

FEMY Earnings Date and Information. Femasys has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.May 26, 2023 · At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. Femasys, a medical device company, ... Its stock ran from $0.33 to an intraday high of $4.75 a few days later, only to fall back to the $1 range. During that flurry of activity, ...Dec 1, 2023 · Femasys (FEMY) stock price is up 1,250% but there are 2 key risks. The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar... 7 weeks ago - Invezz.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/30/2023. S-3. Securities Registration Statement (simplified form) 11/29/2023. 8-K. Current report filing.Sep 27, 2023 · Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products. Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in …Femasys has received 510 (k) Clearance from the FDA for FemaSeed®, an innovative infertility treatment. The clearance allows for the U.S. commercialization of FemaSeed®, which delivers sperm directly to the fallopian tube. FemaSeed® is expected to reduce procedural complications compared to other treatments.Oct 4, 2023 · Publish : 04 Oct 2023, 07:17 PM Update : 04 Oct 2023, 07:17 PM. Femasys (NASDAQ: FEMY) stock is down 50% over night from highs. A reasonable bet would be that FEMY stock will continue to fall back to more reasonable levels. For, as far as we can see at least, this is a flurry of speculation producing far too much movement for the objective ... What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ...FEMY - Femasys Inc Stock Price and Quote Nov-23-23 03:38PM 20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey) Nov-15-23 08:30AM PharmaCyte …WebFemasys ( NASDAQ: FEMY) shares jumped 21% midday Monday following news that the US Food and Drug Administration has approved its investigational device exemption application to begin clinical ...Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.

FEMY Femasys Inc. Stock Price & Overview 646 followers $0.96 0.04 ( +4.88%) 3:59 PM 11/17/23 NASDAQ | $USD | Pre-Market: $0.95 -0.01 (-1.53%) 8:33 AM …Web

-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys --ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible …

Portfolio Overview. Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs. Femasys has an expansive, internally-created intellectual property ... Sep 29, 2023 · Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ...Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late ...Employees: 30. 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, GA 30024. 770-500-3910. femasys.com. Femasys Inc. focuses on women's healthcare market in the United States. The company develops permanent birth …John Dyett has not been actively trading shares of Femasys over the course of the past ninety days. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where conception occurs -. ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in …Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has activated enrollment for its FemBloc trial to investigate a permanent birth control candidate. Shares of FEMY are moving higher on very heavy trading volume.Femasys Inc (NASDAQ: FEMY) has seen a rise in its stock price by 1.31 in relation to its previous close of 0.90. However, the company has experienced a -9.52% decline in its stock price over the last five trading sessions. MarketBeat reported 2023-10-05 that Penny stocks can be a treasure trove of investment opportunities, and […]That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...ACADIA Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACADIA’s stock has increased 40.1% year to date. It beat earnings estimates in two of the last four quarters while ...Instagram:https://instagram. is sofi mortgage goodnasdaq bandjandj credonu ibuy Dec 1, 2023 · Femasys (FEMY) stock price is up 1,250% but there are 2 key risks. The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar... 7 weeks ago - Invezz. Femasys Inc stock performance at a glance. Check Femasys Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. patterson uti energyfutures trading training Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.FEMY : 1.2200 (+0.83%) Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET Globe Newswire - Mon Jul 11, 2022. ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by ... online handyman courses Apr 19, 2023 · In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions. Femasys Inc. FEMY shares are trading lower Tuesday. The stock has been volatile since the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment, towards the end of September. What To Know: On Sept. 26, shares of the stock surged on news of the FDA clearance for FemaSeed, although the stock pulled back the …